ChemGenex Pharmaceuticals Limited was formed in 2004 from the merger of AGT BioSciences of Melbourne, Australia and ChemGenex Therapeutics of Menlo Park, California USA. ChemGenex Therapeutics was focused on applying genomic technologies to the pre-clinical and clinical development of small molecule therapeutics for the treatment of cancer. AGT BioSciences was focused on discovery and validation of novel gene targets associated with cancer, diabetes, obesity and depression. As a combined entity, ChemGenex uses genomic and proteomic technologies from discovery through clinical development.